Table 1.

Summary of the characteristics, efficacy, and adverse effects of SARS-CoV-2 vaccines from the studies included in the review.

Vaccine characteristics	Administration	Efficacy	Adverse effects	Refs
Comirnaty (BNT162b2)
Lipid NP vaccine comprising packaged strands of modified mRNA	Dose regimen: two doses of 0.3 ml (30 μg mRNA), with a 21-day interval between doses A booster dose (third dose) can also be administered at least 6 months after second dose	91.3–100 % efficacy in populations 12 years and older Increased levels of IgG antibodies and virus neutralization Third dose (15 μg) increased anti-S IgG secretion and virus neutralization Also effective against B.1.1.7, B.1.351, and B.1.617.2 variants	Events at local level: pain at injection site, erythema, urticaria, or swelling Mild-to-moderate systemic reactions: fatigue, headache, chills, muscle pain Severe adverse effects: lymphadenopathy, severe chest pain, hypertension, allergy, paroxysmal ventricular arrhythmia, shoulder injury, paresthesia in right leg	[13], [14], [16], [17], [19], [21], [22], [23], [24], [25], [26], [27], [28], [29], [31], [32], [33], [34]
Spikevax (mRNA-1273)
Nucleoside-modified mRNA vaccine	Dose regimen in persons 12 years and older: two doses of 100 μg (0.5 ml) In children 6–11-year old: two doses of 50 μg (0.25 ml) each	93.2–94.1 % efficacy After second dose, increase in IgG anti-RBD and anti-S antibodies observed Neutralized wild-type, B.1.1.7, B.1.351, P.1, and B.1.617.2 variants	Mild adverse events at local level: pain at puncture site, erythema, induration or swelling, itching, and lymphadenopathy Most-frequent mild-to-moderate systemic reactions: headache, fatigue, myalgia, arthralgia. Serious adverse effects (cardiorespiratory arrest, hypersensitivity reaction, thrombotic events, pericarditis, death, and Bell’s palsy) could not be attributed to vaccine because of limited data	[37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
Janssen (Ad26.COV2.S)
Monovalent vaccine comprising adenovirus vector without replicative capacity type 26 human adenovirus	Dose regimen: in persons aged 18 years or older, single dose of 0.5 ml (5 × 1010 viral particles)	52.9–66.1 % efficacy at 28 days after administration To prevent severe disease, efficacy was 85.4 % at 28 days post-vaccination Effective against B.1.1.7, B.1.617.2, P.1, C.37, and B.1.621 variants Administration of booster dose in patients with blood cancers generated immune response against COVID-19 Number of anti-S IgG antibodies similar in patients aged 18–55 and 65 years and older	Most-frequent local reaction: pain at site injection Systemic reactions: headache, fatigue, myalgia, nausea, fever Severe reactions: lymphadenopathy, Guillain–Barré syndrome and thrombosis combined with thrombocytopenia or immune thrombocytopenia, anaphylaxis and capillary leak syndrome	[53], [54], [55], [57], [58], [59], [60]
Vaxzevria (ChAdOx1 nCoV-19)
Replication-deficient recombinant adenovirus vector-based vaccine	Dose regimen: two doses of 0.5 ml intramuscularly	74 % efficacy 15 days after second dose Hospitalization and death because of COVID-19 reduced after vaccination Effective against wild-type and B.1 0.35, B.1.1.7, B.1.351, P.1, and P.2 variants	Most-frequent (mild to moderate) local and systemic effects: injection site pain, headache, decreased appetite, hyperthermia, fatigue, muscle pain Severe adverse events: vaccine-induced immune thrombotic thrombocytopenia, hemorrhage, anaphylaxis, Guillain–Barré syndrome, late inflammatory skin reactions, bleeding episodes, death	[61], [62], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88]
Nuvaxovid (NVX-CoV2373)
Recombinant, adjuvanted, full-length, purified protein S subunit vaccine, stabilized in its prefusion conformation	Dose regimen: two doses of 0.5 ml with interdose interval of 3–4 weeks	90.4–100 % efficacy against moderate-to-severe disease Synergic action of NVX-CoV2373 and influenza virus vaccine showed an efficacy of 89.7 % 86.3 % efficacy against B.1.1.7 variant	Local and systemic adverse effects: headache, nausea and vomiting, myalgia, arthralgia, injection site tenderness, injection site pain, fatigue, malaise, redness and/or swelling at injection site, fever, chills, pain in extremities, lymphadenopathy, hypertension, rash, erythema, pruritus, urticaria	[89], [90], [93], [94], [95], [96], [97], [98], [99]